Symbia IntevoSPECT/CT that improves your image

A SPECT/CT myocardial perfusion scan showed no sign of significant stress-induced ischemia or transmural scars, nor inferior and posterior wall attenuation with CTAC. The normal ejection fraction (EF) was 78%.

SPECT/CT localizes multiple tracer-avid somatostatin receptor-rich hepatic metastases, thereby helping in accurate localization of lesions and differentiation of lesion from physiological uptake.

SPECT/CT imaging precisely defines a small peri-auricular sentinel lymph node due to accurate coregistration of anatomical information from the CT, with focal tracer uptake in the sentinel node seen on SPECT, allowing for precise surgical removal.

SPECT/CT-enabled localization of exact anatomical position of the parathyroid adenoma, which helped guide precise surgical exploration.

CT shows focal hypodense liver lesions with absence of tracer uptake on SPECT. Correlation of anatomical information of liver lesions by CT and hepatocyte function by SPECT helps characterize the liver cysts.

xSPECT Quant™ across multiple time points quantifies the decrease of metabolic activity in the bone in a patient with metastases from prostate cancer. In addition, the uptake measured during anti-androgen therapy at the three time points correlated with a decline of prostate-specific antigen (PSA).

xSPECT Bone™ and xSPECT Quant™ show grossly increased skeletal metabolism in bony mass (SUV_max 91.7) in the upper part of right fibula. The pattern of well-defined focal lytic areas on the CT, with heterogeneous uptake pattern on xSPECT Bone, is strongly suggestive of giant cell tumor of proximal fibula.

In addition to a visual read of a SPECT/CT study, xSPECT Quant™ using ¹²³I in ¹²³I-Ioflupane enables standardized quantification assessment to aid in diagnosis in equivocal motion disorders.

xSPECT Quant™ aids in neuroendocrine tumor (NET) assessment with SPECT/CT by determining changes in tumoral and non-tumoral tracer concentration in order to determine tracer retention within lesions and washout in critical organs.

Sequential SPECT/CT with xSPECT Quant™, performed at multiple time points, was used to assess renal and tumor absorbed dose. Studies showed significant response of tumor with shrinkage ,as well as significant reduction in uptake, compared to previous study suggesting positive response to radionuclide therapy.

A SPECT/CT study was conducted for evaluation of skeletal pathology. SPECT/CT images confirmed increased radiographic tracer uptake. These findings are consistent with osteitis pubis and degenerative changes of the lower lumbar spine.

xSPECT Bone™ shows sharp delineation of focal increased uptake corresponding to a chronic left L5 pars defect, as well as an incompletely healed fracture in the right lamina of the L5 vertebra.

xSPECT Bone™ sharply delineates hypermetabolism at the scaphoid articular surface of the scaphoid-trapezium joint, which reflects bone remodeling secondary to adjacent healed scaphoid fracture following trauma.

A SPECT/CT study to assess the severity and extent of fracture and the status of right femoral head. xSPECT Bone™ sharply delineates the fracture lines, including fragmented bony margins, thereby helping visualize the displaced fragments and their relationship to adjacent soft tissue.

A SPECT/CT myocardial perfusion scan showed no sign of significant stress-induced ischemia or transmural scars, nor inferior and posterior wall attenuation with CTAC. The normal ejection fraction (EF) was 78%.